StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a report published on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Stock Down 6.5 %
Shares of NASDAQ:RDHL opened at $3.60 on Tuesday. RedHill Biopharma has a 12-month low of $3.01 and a 12-month high of $20.27. The business has a fifty day simple moving average of $5.81 and a 200 day simple moving average of $14.98.
Institutional Investors Weigh In On RedHill Biopharma
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC purchased a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent filing with the SEC. Institutional investors own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
See Also
- Five stocks we like better than RedHill Biopharma
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What is Put Option Volume?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Why Are These Companies Considered Blue Chips?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
